1
|
RuizdelRio J, Muñoz P, Carreira P, Maestro D, Pablos JL, Palanca A, Merino J, Serrano-Mollar A, Merino R, Tamayo E, Lopez-Hoyos M, Diaz-Gonzalez F, Martinez-Taboada V, Villar AV. Profibrotic Role of Inducible Heat Shock Protein 90α Isoform in Systemic Sclerosis. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2022; 209:38-48. [PMID: 35715007 DOI: 10.4049/jimmunol.2100430] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 04/22/2022] [Indexed: 11/19/2022]
Abstract
Systemic sclerosis (SSc) is an autoimmune disease that affects skin and multiple internal organs. TGF-β, a central trigger of cutaneous fibrosis, activates fibroblasts with the involvement of the stress-inducible chaperone heat shock protein 90 isoform α (Hsp90α). Available evidence supports overexpression and secretion of Hsp90α as a feature in profibrotic pathological conditions. The aim of this work is to investigate the expression and function of Hsp90α in experimental models of skin fibrosis such as human fibroblasts, C57BL/6 mice, and in human SSc. For this purpose, we generated a new experimental model based on doxorubicin administration with improved characteristics with respect to the bleomycin model. We visualized disease progression in vivo by fluorescence imaging. In this work, we obtained Hsp90α mRNA overexpression in human skin fibroblasts, in bleomycin- and doxorubicin-induced mouse fibrotic skin, and in lungs of bleomycin- and doxorubicin-treated mice. Hsp90α-deficient mice showed significantly decreased skin thickness compared with wild-type mice in both animal models. In SSc patients, serum Hsp90α levels were increased in patients with lung involvement and in patients with the diffuse form of SSc (dSSc) compared with patients with the limited form of SSc. The serum Hsp90α levels of patients dSSc were correlated with the Rodnan score and the forced vital capacity variable. These results provide new supportive evidence of the contribution of the Hsp90α isoform in the development of skin fibrosis. In SSc, these results indicated that higher serum levels were associated with dSSc and lung fibrosis.
Collapse
Affiliation(s)
- Jorge RuizdelRio
- Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, Santander, Spain.,Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Pedro Muñoz
- Gerencia Atención Primaria, Servicio Cántabro de Salud, Santander, Spain
| | - Patricia Carreira
- Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - David Maestro
- Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, Santander, Spain.,Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Jose L Pablos
- Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
| | - Ana Palanca
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.,Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, Spain
| | - Jesus Merino
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.,Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain
| | - Anna Serrano-Mollar
- Departamento de Patología Experimental, Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC-IDIBAPS), Barcelona, Spain.,Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias, Madrid, Spain
| | - Ramon Merino
- Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, Santander, Spain.,Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.,SODERCAN, Santander, Spain
| | - Esther Tamayo
- Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain
| | - Marcos Lopez-Hoyos
- Servicio de Inmunología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Federico Diaz-Gonzalez
- Facultad de Medicina, Universidad de La Laguna, Servicio de Reumatología, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain
| | - Victor Martinez-Taboada
- Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, IDIVAL, Facultad de Medicina, Universidad de Cantabria, Santander, Spain; and
| | - Ana V Villar
- Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, Santander, Spain; .,Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.,Departamento de Fisiología y Farmacología, Universidad de Cantabria, Santander, Spain
| |
Collapse
|
2
|
Bredemeier M. Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 2021; 74:733-734. [PMID: 34612018 DOI: 10.1002/art.41993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 09/21/2021] [Indexed: 11/10/2022]
Abstract
We congratulate the authors for the excellent review, not only restricted to recently approved therapies, on the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (1). However, it is our opinion that some aspects that currently affect our medical practice merit further commentary. The pandemic of COVID-19 has generated unique challenges in the therapy of SSc-ILD, especially impacting the decision to start treatment. While there is no evidence suggesting that cyclophosphamide or rituximab can reduce mortality in SSc-ILD (2), these drugs have been associated with higher incidence of serious outcomes and mortality in COVID-19 patients (3, 4).
Collapse
Affiliation(s)
- Markus Bredemeier
- Rheumatology Service at Hospital Nossa Senhora da Conceição, Grupo Hospitalar Conceição, Porto Alegre, RS, Brazil
| |
Collapse
|
3
|
Seibold JR, Kohlbrenner V, Alves M, Distler O. Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier. Ann Rheum Dis 2020; 81:e251. [PMID: 33023957 DOI: 10.1136/annrheumdis-2020-218960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 09/10/2020] [Indexed: 11/03/2022]
Affiliation(s)
- James R Seibold
- Scleroderma Research Consultants LLC, Aiken, South Carolina, USA
| | | | - Margarida Alves
- Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
| | - Oliver Distler
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|